Cross Country Healthcare Announces Second Quarter 2016 Financial Results
-
Revenue was
$199.4 million compared to$192.6 million , up 4% year-over-year -
Adjusted EBITDA was
$11.1 million , or 5.5% of revenue versus$8.2 million , or 4.2% of revenue in the prior year, up 35% year-over-year -
Adjusted EPS was
$0.16 compared to$0.10 in the prior year -
GAAP net loss was
$17.2 million , or$0.54 per diluted share, including non-cash impairment charges and a loss on derivative liability -
Cash flow from operations was
$10.3 million compared to$5.7 million in the prior year
Note: Refer to table and discussion of Non-GAAP financial measures below.
"For the second quarter this year, we again exceeded guidance for Gross
Profit and Adjusted EBITDA Margins driven by strong pricing and leverage
from revenue growth," said
Second quarter consolidated revenue was
For the six months ended
Quarterly Business Segment Highlights
Nurse and
Revenue from Nurse and
Revenue from
Other Human Capital Management Services
Revenue from Other Human Capital Management Services was
Cash Flow and Balance Sheet Highlights
Cash flow provided by operating activities was
At
Outlook for Third Quarter and Full Year 2016
Q3 2016 Range | Year-over-Year | |||
Change | ||||
Revenue |
|
2% - 5% | ||
Gross profit margin | 26.7% - 27.2% | 40 - 90 bps | ||
Adjusted EBITDA margin | 5.0% -5.5% | (130) - (80) bps | ||
Adjusted EPS |
|
|
||
FY 2016 Range | Year-over-Year | |||
Change | ||||
Revenue |
|
4% - 6% | ||
Adjusted EBITDA margin | 5.5% - 6.0% | 60 - 110 bps |
The estimates above are based on current management expectations and, as such, are forward-looking and actual results may differ materially. These ranges do not include the potential impact of any future divestitures, mergers, acquisitions or other business combinations, any impairment charges or valuation allowances, any acquisition-related measurement period adjustments, or any material legal or restructuring charges.
INVITATION TO CONFERENCE CALL
The Company will hold its quarterly conference call on
ABOUT
Copies of this and other news releases as well as additional information
about
NON-GAAP FINANCIAL MEASURES
This press release and accompanying financial statement tables reference
non-GAAP financial measures. Such non-GAAP financial measures are
provided as additional information and should not be considered
substitutes for, or superior to, financial measures calculated in
accordance with
FORWARD LOOKING STATEMENT
In addition to historical information, this press release contains
statements relating to our future results (including certain projections
and business trends) that are "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), and are subject to the "safe harbor" created by those
sections. Forward-looking statements consist of statements that are
predictive in nature, depend upon or refer to future events. Words such
as "expects", "anticipates", "intends", "plans", "believes",
"estimates", "suggests", "appears", "seeks", "will", and variations of
such words and similar expressions are intended to identify
forward-looking statements. Forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause our actual
results and performance to be materially different from any future
results or performance expressed or implied by these forward-looking
statements. These factors include, but are not limited to, the
following: our ability to attract and retain qualified nurses,
physicians and other healthcare personnel, costs and availability of
short-term housing for our travel healthcare professionals, demand for
the healthcare services we provide, both nationally and in the regions
in which we operate, the functioning of our information systems, the
effect of cyber security risks and cyber incidents on our business, the
effect of existing or future government regulation and federal and state
legislative and enforcement initiatives on our business, our clients'
ability to pay us for our services, our ability to successfully
implement our acquisition and development strategies, including our
ability to successfully integrate acquired businesses and realize
synergies from such acquisitions, the effect of liabilities and other
claims asserted against us, the effect of competition in the markets we
serve, our ability to successfully defend the Company, its subsidiaries,
and its officers and directors on the merits of any lawsuit or determine
its potential liability, if any, and other factors set forth in Item 1A.
"Risk Factors" in the Company's Annual Report on Form 10-K for the year
ended
Although we believe that these statements are based upon reasonable
assumptions, we cannot guarantee future results and readers are
cautioned not to place undue reliance on these forward-looking
statements, which reflect management's opinions only as of the date of
this press release. There can be no assurance that (i) we have correctly
measured or identified all of the factors affecting our business or the
extent of these factors' likely impact, (ii) the available information
with respect to these factors on which such analysis is based is
complete or accurate, (iii) such analysis is correct or (iv) our
strategy, which is based in part on this analysis, will be successful.
The Company undertakes no obligation to update or revise forward-looking
statements. All references to "we", "us", "our", or "Cross Country" in
this press release mean
|
|||||||||||||||||||||||
Consolidated Statements of Operations | |||||||||||||||||||||||
(Unaudited, amounts in thousands, except per share data) | |||||||||||||||||||||||
Three Months Ended | Six Months Ended | ||||||||||||||||||||||
|
|
|
|
|
|||||||||||||||||||
2016 | 2015 | 2016 | 2016 | 2015 | |||||||||||||||||||
Revenue from services | $ | 199,443 | $ | 192,617 | $ | 196,583 | $ | 396,026 | $ | 378,581 | |||||||||||||
Operating expenses: | |||||||||||||||||||||||
Direct operating expenses | 144,597 | 144,254 | 145,537 | 290,134 | 283,181 | ||||||||||||||||||
Selling, general and administrative expenses | 44,675 | 40,891 | 42,933 | 87,608 | 82,057 | ||||||||||||||||||
Bad debt expense | 228 | 131 | 249 | 477 | 222 | ||||||||||||||||||
Depreciation | 1,059 | 989 | 1,005 | 2,064 | 1,949 | ||||||||||||||||||
Amortization | 1,406 | 983 | 1,407 | 2,813 | 1,965 | ||||||||||||||||||
Acquisition and integration costs (a) | — | 40 | — | — | 158 | ||||||||||||||||||
Acquisition-related contingent consideration (b) | 183 | — | 287 | 470 | — | ||||||||||||||||||
Restructuring costs | — | 1,007 | — | — | 1,007 | ||||||||||||||||||
Impairment charges (c) | 24,311 | — | — | 24,311 | — | ||||||||||||||||||
Total operating expenses | 216,459 | 188,295 | 191,418 | 407,877 | 370,539 | ||||||||||||||||||
(Loss) income from operations | (17,016 | ) | 4,322 | 5,165 | (11,851 | ) | 8,042 | ||||||||||||||||
Other expenses (income): | |||||||||||||||||||||||
Interest expense | 1,608 | 1,772 | 1,635 | 3,243 | 3,509 | ||||||||||||||||||
Loss (gain) on derivative liability (d) | 3,571 | (362 | ) | (16,436 | ) | (12,865 | ) | (2,509 | ) | ||||||||||||||
Loss on early extinguishment of debt (e) | 1,568 | — | — | 1,568 | — | ||||||||||||||||||
Other (income) expense, net | (34 | ) | 27 | (17 | ) | (51 | ) | 70 | |||||||||||||||
(Loss) income before income taxes | (23,729 | ) | 2,885 | 19,983 | (3,746 | ) | 6,972 | ||||||||||||||||
Income tax (benefit) expense | (6,634 | ) | 205 | 797 | (5,837 | ) | 1,242 | ||||||||||||||||
Consolidated net (loss) income | (17,095 | ) | 2,680 | 19,186 | 2,091 | 5,730 | |||||||||||||||||
Less: Net income attributable to noncontrolling interest in subsidiary | 142 | 107 | 164 | 306 | 223 | ||||||||||||||||||
Net (loss) income attributable to common shareholders | $ | (17,237 | ) | $ | 2,573 | $ | 19,022 | $ | 1,785 | $ | 5,507 | ||||||||||||
Net (loss) income per share attributable to common shareholders - Basic | $ | (0.54 | ) | $ | 0.08 | $ | 0.60 | $ | 0.06 | $ | 0.18 | ||||||||||||
Net (loss) income per share attributable to common shareholders - Diluted | $ | (0.54 | ) | $ | 0.08 | $ | 0.09 | $ | (0.26 | ) | $ | 0.13 | |||||||||||
Weighted average common shares outstanding: | |||||||||||||||||||||||
Basic | 32,085 | 31,398 | 31,956 | 32,021 | 31,346 | ||||||||||||||||||
Diluted (f) | 32,085 | 32,040 | 36,180 | 36,194 | 35,508 |
|
|||||||||||||||||||||||
Reconciliation of Non-GAAP Financial Measures | |||||||||||||||||||||||
(Unaudited, amounts in thousands) | |||||||||||||||||||||||
Three Months Ended | Six Months Ended | ||||||||||||||||||||||
|
|
|
|
|
|||||||||||||||||||
2016 | 2015 | 2016 | 2016 | 2015 | |||||||||||||||||||
Adjusted EBITDA: (g) | |||||||||||||||||||||||
Consolidated net (loss) income attributable to common shareholders | $ | (17,237 | ) | $ | 2,573 | $ | 19,022 | $ | 1,785 | $ | 5,507 | ||||||||||||
Depreciation and amortization | 2,465 | 1,972 | 2,412 | 4,877 | 3,914 | ||||||||||||||||||
Interest expense | 1,608 | 1,772 | 1,635 | 3,243 | 3,509 | ||||||||||||||||||
Income tax expense | (6,634 | ) | 205 | 797 | (5,837 | ) | 1,242 | ||||||||||||||||
Acquisition and integration costs (a) | — | 40 | — | — | 158 | ||||||||||||||||||
Acquisition-related contingent consideration (b) | 183 | — | 287 | 470 | — | ||||||||||||||||||
Restructuring costs | — | 1,007 | — | — | 1,007 | ||||||||||||||||||
Impairment charges (c) | 24,311 | — | — | 24,311 | — | ||||||||||||||||||
Loss (gain) on derivative liability (d) | 3,571 | (362 | ) | (16,436 | ) | (12,865 | ) | (2,509 | ) | ||||||||||||||
Loss on early extinguishment of debt (e) | 1,568 | — | — | 1,568 | — | ||||||||||||||||||
Other (income) expense, net | (34 | ) | 27 | (17 | ) | (51 | ) | 70 | |||||||||||||||
Equity compensation | 1,119 | 840 | 648 | 1,767 | 1,216 | ||||||||||||||||||
Net income attributable to noncontrolling interest in subsidiary | 142 | 107 | 164 | 306 | 223 | ||||||||||||||||||
Adjusted EBITDA (g) | $ | 11,062 | $ | 8,181 | $ | 8,512 | $ | 19,574 | $ | 14,337 | |||||||||||||
Adjusted EPS: (h) | |||||||||||||||||||||||
Reported diluted EPS | $ | (0.54 | ) | $ | 0.08 | $ | 0.09 | $ | (0.26 | ) | $ | 0.13 | |||||||||||
Pre-tax: | |||||||||||||||||||||||
Acquisition-related contingent consideration (b) | 0.01 | — | 0.01 | 0.01 | — | ||||||||||||||||||
Restructuring costs | — | 0.03 | — | — | 0.03 | ||||||||||||||||||
Loss on early extinguishment of debt (e) | 0.05 | — | — | 0.05 | — | ||||||||||||||||||
Impairment charges (c) | 0.74 | — | — | 0.74 | — | ||||||||||||||||||
Loss (gain) on derivative liability (d) | 0.11 | (0.01 | ) | (0.50 | ) | (0.39 | ) | (0.08 | ) | ||||||||||||||
Taxes: | |||||||||||||||||||||||
Tax effect of items (excluding impairment charges) | (0.06 | ) | (0.01 | ) | 0.20 | 0.13 | 0.02 | ||||||||||||||||
Valuation allowance on adjusted items | 0.06 | 0.01 | (0.20 | ) | (0.13 | ) | (0.02 | ) | |||||||||||||||
Tax effect of impairment charges | (0.22 | ) | — | — | (0.22 | ) | — | ||||||||||||||||
Adjustment for change in dilutive shares (h) | 0.01 | — | 0.49 | 0.32 | 0.04 | ||||||||||||||||||
Adjusted EPS (h) | $ | 0.16 | $ | 0.10 | $ | 0.09 | $ | 0.25 | $ | 0.12 | |||||||||||||
Reported weighted average common shares outstanding - diluted | 32,085 | 32,040 | 36,180 | 36,194 | 35,508 | ||||||||||||||||||
Adjustment to diluted shares (h) | 601 | — | (3,521 | ) | (3,521 | ) | (3,521 | ) | |||||||||||||||
Adjusted weighted average common shares - diluted | 32,686 | 32,040 | 32,659 | 32,673 | 31,987 |
|
|||||||||
Consolidated Balance Sheets | |||||||||
(Unaudited, amounts in thousands) | |||||||||
|
|
||||||||
2016 | 2015 | ||||||||
Assets | |||||||||
Current assets: | |||||||||
Cash and cash equivalents | $ | 10,229 | $ | 2,453 | |||||
Accounts receivable, net | 144,611 | 146,873 | |||||||
Prepaid expenses | 5,070 | 4,521 | |||||||
Insurance recovery receivable | 2,811 | 2,866 | |||||||
Other current assets | 1,714 | 2,032 | |||||||
Total current assets | 164,435 | 158,745 | |||||||
Property and equipment, net | 11,018 | 10,470 | |||||||
|
77,376 | 95,096 | |||||||
Intangible assets, net (excluding goodwill) | 73,510 | 82,914 | |||||||
Debt issuance costs, net | 1,017 | 376 | |||||||
Other non-current assets | 17,010 | 17,994 | |||||||
Total assets | $ | 344,366 | $ | 365,595 | |||||
Liabilities and Stockholders' Equity | |||||||||
Current liabilities: | |||||||||
Accounts payable and accrued expenses | $ | 38,224 | $ | 41,098 | |||||
Accrued employee compensation and benefits | 28,964 | 29,402 | |||||||
Current portion of long-term debt and capital lease obligations | 2,033 | 8,071 | |||||||
Deferred purchase price | — | 2,184 | |||||||
Other current liabilities | 4,701 | 5,291 | |||||||
Total current liabilities | 73,922 | 86,046 | |||||||
Long-term debt and capital lease obligations | 77,738 | 81,301 | |||||||
Non-current deferred tax liabilities | 12,188 | 18,475 | |||||||
Long-term accrued claims | 28,532 | 30,070 | |||||||
Contingent consideration | 2,754 | 3,533 | |||||||
Other long-term liabilities | 4,955 | 4,826 | |||||||
Total liabilities | 200,089 | 224,251 | |||||||
Commitments and contingencies | |||||||||
Stockholders' equity: | |||||||||
Common stock | 3 | 3 | |||||||
Additional paid-in capital | 255,310 | 254,108 | |||||||
Accumulated other comprehensive loss | (1,234 | ) | (1,207 | ) | |||||
Accumulated deficit | (110,272 | ) | (112,056 | ) | |||||
Total |
143,807 | 140,848 | |||||||
Noncontrolling interest | 470 | 496 | |||||||
Total stockholders' equity | 144,277 | 141,344 | |||||||
Total liabilities and stockholders' equity | $ | 344,366 | $ | 365,595 |
|
||||||||||||||||||
Segment Data (i) | ||||||||||||||||||
(Unaudited, amounts in thousands) | ||||||||||||||||||
Three Months Ended | % Change Fav/(Unfav) | |||||||||||||||||
|
% of |
|
% of |
|
% of | Year-over- | ||||||||||||
2016 | Total | 2015 | Total | 2016 | Total | Year | Sequential | |||||||||||
Revenue from services: | ||||||||||||||||||
Nurse and |
$ | 172,048 | 86% | $ | 152,677 | 79% | $ | 168,765 | 86% | 13% | 2% | |||||||
|
23,927 | 12% | 29,794 | 16% | 24,453 | 12% | (20)% | (2)% | ||||||||||
Other Human Capital Management Services | 3,468 | 2% | 10,146 | 5% | 3,365 | 2% | (66)% | 3% | ||||||||||
$ | 199,443 | 100% | $ | 192,617 | 100% | $ | 196,583 | 100% | 4% | 1% | ||||||||
Contribution income: (j) | ||||||||||||||||||
Nurse and |
$ | 17,615 | $ | 12,821 | $ | 16,790 | 37% | 5% | ||||||||||
|
2,050 | 2,228 | 1,553 | (8)% | 32% | |||||||||||||
Other Human Capital Management Services | 69 | 747 | (111) | (91)% | 162% | |||||||||||||
19,734 | 15,796 | 18,232 | 25% | 8% | ||||||||||||||
Unallocated corporate overhead (k) | 9,791 | 8,455 | 10,368 | (16)% | 6% | |||||||||||||
Depreciation | 1,059 | 989 | 1,005 | (7)% | (5)% | |||||||||||||
Amortization | 1,406 | 983 | 1,407 | (43)% | —% | |||||||||||||
Acquisition and integration costs (a) | — | 40 | — | 100% | —% | |||||||||||||
Acquisition-related contingent consideration (b) | 183 | — | 287 | (100)% | 36% | |||||||||||||
Restructuring costs | — | 1,007 | — | 100% | —% | |||||||||||||
Impairment charges (c) | 24,311 | — | — | (100)% | (100)% | |||||||||||||
(Loss) income from operations | $ | (17,016 | ) | $ | 4,322 | $ | 5,165 | (494)% | (429)% | |||||||||
Six Months Ended |
% Change |
|||||||||||||||||
|
% of |
|
% of |
Year-over- |
||||||||||||||
2016 | Total | 2015 | Total | |||||||||||||||
Revenue from services: | ||||||||||||||||||
Nurse and |
$ | 340,813 | 86% | $ | 301,789 | 80% | 13% | |||||||||||
|
48,380 | 12% | 57,141 | 15% | (15)% | |||||||||||||
Other Human Capital Management Services | 6,833 | 2% | 19,651 | 5% | (65)% | |||||||||||||
$ | 396,026 | 100% | $ | 378,581 | 100% | 5% | ||||||||||||
Contribution income: (j) | ||||||||||||||||||
Nurse and |
$ | 34,405 | $ | 23,723 | 45% | |||||||||||||
|
3,603 | 4,344 | (17)% | |||||||||||||||
Other Human Capital Management Services | (42 | ) | 1,349 | (103)% | ||||||||||||||
37,966 | 29,416 | 29% | ||||||||||||||||
Unallocated corporate overhead (k) | 20,159 | 16,295 | (24)% | |||||||||||||||
Depreciation | 2,064 | 1,949 | (6)% | |||||||||||||||
Amortization | 2,813 | 1,965 | (43)% | |||||||||||||||
Acquisition and integration costs (a) | — | 158 | 100% | |||||||||||||||
Acquisition-related contingent consideration (b) | 470 | — | (100)% | |||||||||||||||
Restructuring costs | — | 1,007 | 100% | |||||||||||||||
Impairment charges (c) | 24,311 | — | (100)% | |||||||||||||||
(Loss) income from operations | $ | (11,851 | ) | $ | 8,042 | (247)% |
|
||||||||||||||||||||||
Other Financial Data | ||||||||||||||||||||||
(Unaudited) | ||||||||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||||||||
|
|
|
|
|
||||||||||||||||||
2016 | 2015 | 2016 | 2016 | 2015 | ||||||||||||||||||
Net cash provided by (used in) operating activities (in thousands) | $ | 10,303 | $ | 5,727 | $ | 2,564 | $ | 12,867 | $ | 5,997 | ||||||||||||
Nurse and |
||||||||||||||||||||||
FTEs (l) | 6,884 | 6,607 | 6,817 | 6,850 | 6,531 | |||||||||||||||||
Average Nurse and |
$ | 275 | $ | 254 | $ | 272 | $ | 273 | $ | 255 | ||||||||||||
|
||||||||||||||||||||||
Days filled (n) | 14,480 | 20,282 | 16,842 | 31,322 | 38,926 | |||||||||||||||||
Revenue per day filled (o) | $ | 1,525 | $ | 1,468 | $ | 1,521 | $ | 1,523 | $ | 1,475 |
(a) Acquisition and integration costs for the three and six months ended
(b) Acquisition-related contingent consideration represents the
accretion adjustment to the contingent consideration liability for the
Mediscan acquisition that closed on
(c) The three months and six months ended
(d) Loss (gain) on derivative liability represents the change in the fair value of embedded features of our convertible notes.
(e) Loss on early extinguishment of debt relates to the write-off of unamortized net debt discount and issuance costs as well as transaction fees and expenses related to the extinguishment of the Company's subordinated term loan.
(f) When applying the if-converted method to our Convertible Notes,
3,521,126 shares are not included in diluted weighted average shares for
the three months ended
(g) Adjusted EBITDA, a non-GAAP (Generally Accepted Accounting Principles) financial measure, is defined as net income (loss) attributable to common shareholders before depreciation, amortization, interest expense, income tax expense, acquisition and integration costs, acquisition-related contingent consideration, restructuring costs, impairment charges, loss (gain) on derivative liability, loss on early extinguishment of debt, other (income) expense, net, equity compensation, and includes net income attributable to noncontrolling interest in subsidiary. Adjusted EBITDA should not be considered a measure of financial performance under GAAP. Management presents Adjusted EBITDA because it believes that Adjusted EBITDA is a useful supplement to net income (loss) attributable to common shareholders as an indicator of operating performance. Management uses Adjusted EBITDA for planning purposes and as one performance measure in its annual cash incentive program for certain members of its management team. Adjusted EBITDA, as defined, closely matches the operating measure typically used in the Company's credit facilities in calculating various ratios. Adjusted EBITDA Margin is calculated by dividing Adjusted EBITDA by the Company's consolidated revenue.
(h) Adjusted EPS, a non-GAAP financial measure, is defined as net income
(loss) attributable to common shareholders per diluted share (reported
EPS) before the diluted EPS impact of acquisition and integration costs,
acquisition-related contingent consideration, restructuring costs, loss
on early extinguishment and modification of debt, impairment charges,
and loss (gain) on derivative liability. Adjusted EPS should not be
considered a measure of financial performance under GAAP. Management
presents Adjusted EPS because it believes that Adjusted EPS is a useful
supplement to its reported EPS as an indicator of operating performance.
Management uses Adjusted EPS as one performance measure in its annual
cash incentive program for certain members of its management team.
Management believes it provides a more useful comparison of the
Company's underlying business performance from period to period and is
more representative of the future earnings capacity of the Company. For
the three months ended
(i) Segment data provided is in accordance with the Segment Reporting Topic of the FASB ASC.
(j) Contribution income is defined as income from operations before depreciation, amortization, acquisition and integration costs, acquisition-related contingent consideration, restructuring costs, impairment charges and corporate expenses not specifically identified to a reporting segment. Contribution income is a financial measure used by management when assessing segment performance.
(k) Unallocated corporate overhead includes corporate compensation and benefits, and general and administrative expenses including rent and utilities, computer supplies and expenses, insurance, professional expenses, corporate-wide projects (initiatives), and public company expenses.
(l) FTEs represent the average number of Nurse and
(m) Average revenue per FTE per day is calculated by dividing the Nurse
and
(n) Days filled is calculated by dividing the total hours invoiced during the period by 8 hours.
(o) Revenue per day filled is calculated by dividing revenue invoiced by days filled for the period presented.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160803006621/en/
President
and Chief Executive Officer
wgrubbs@crosscountry.com
Source:
News Provided by Acquire Media